---
title: "Asfotase Alfa - Hypophosphatasia"
sidebar: mydoc_sidebar
permalink: db09105-mesh-d007014-1.html
toc: false 
---


Path ID: `DB09105_MESH_D007014_1`
{% include image.html url="images/db09105-mesh-d007014-1.png" file="db09105-mesh-d007014-1.png" alt="db09105-mesh-d007014-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| <a href="https://identifiers.org/MESH:C570710">MESH:C570710 </a> | asfotase alfa | Drug |
| <a href="https://identifiers.org/MESH:C107241">MESH:C107241 </a> | inorgainc pyrophosphate | ChemicalSubstance |
| <a href="https://identifiers.org/GO:0030282">GO:0030282 </a> | hydroxpatite crystal growth | BiologicalProcess |
| <a href="https://identifiers.org/HP:0004349">HP:0004349 </a> | Reduced bone mineral density | PhenotypicFeature |
| <a href="https://identifiers.org/MESH:D007014">MESH:D007014 </a> | Hypophosphatasia | Disease |
|------------|------|---------|

## Relationships


NOTE: predicates are annotated in <a href="https://github.com/biolink/biolink-model/releases/tag/v1.3.0">Biolink Model (v1.3.0)</a>

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Asfotase Alfa | DECREASES ABUNDANCE OF | Inorgainc Pyrophosphate |
| Inorgainc Pyrophosphate | NEGATIVELY REGULATES | Hydroxpatite Crystal Growth |
| Hydroxpatite Crystal Growth | HAS PHENOTYPE | Reduced Bone Mineral Density |
| Reduced Bone Mineral Density | MANIFESTATION OF | Hypophosphatasia |
|---------|-----------|---------|

Reference:
  - [https://go.drugbank.com/drugs/DB09105#mechanism-of-action](https://go.drugbank.com/drugs/DB09105#mechanism-of-action){:target="_blank"}